{"denoms":[{"counts":[{"groupId":"BG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.\n\nMLN9708","id":"BG000","title":"MLN9708"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"55","upperLimit":"74","value":"70"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Cutaneous T-cell Lymphoma (CTCL)"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Peripheral T-cell Lymphoma (PTCL)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"T-Cell Lymphoma Subtype","unitOfMeasure":"Participants"}],"populationDescription":"12 analyzable patients"}